press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

08 janurary 2020

ling fan, deputy director of china national center for biotechnology development, and her delegation visited alphamab oncology on january 7, 2020, ms. ling fan, deputy director of china national center for biotechnology development, and her delegation visited alphamab oncology. dr. ting xu, founder, chairman and ceo of alpham...
07 janurary 2020

jiangsu alphamab reaches clinical collaboration with zelgen to develop the combination therapy of kn046 and donafenib based on the extensive anticancer spectrum of kn046 and donafenib, the clinical development of this combination therapy may bring significant benefits to patients with advanced cancer.
31 december 2019

nanping xu, vice minister of the ministry of science and technology of china, visited alphamab oncology during the visit, vice minister xu inquired about alphamab oncology's development status, r&d capabilities and post-ipo commercialization strategy. after in-depth understanding of alphamab oncolo...
27 december 2019

alphamab oncology completes dosing for first patient in kn019 phase ii clinical trial for rheumatoid arthritis treatment alphamab oncology (stock code: hk 9966) recently announced that the first patient has been successfully dosed in a phase ii clinical trial (“kn019-201”) of kn019, a ctla-4-based immunosuppressant fu...
18 december 2019

alphamab oncology reaches partnership agreement with 3d medicines and tracon pharmaceuticals for development and commercialization of kn035 in soft tissue sarcoma in north america the collaboration is an important part of kn035 global development strategy.
13 december 2019

9966. hk - remain true to our original aspiration and start our next journey we warmly celebrate that alphamab oncology’s successful listing in hong kong!
23 october 2019

dr. ting xu presides over scientist forum; alphamab oncology appears at the 11th china pharmaceutical conference for entrepreneurs, scientists and investors alphamab oncology was invited to the conference, and dr. ting xu, the founder, chairman and ceo of the company, was invited to preside over the scientist forum. dr. xu shared his experience and insigh...
11 september 2019

kn046 research findings to be presented at csco 2019 alphamab oncology announced that two clinical study abstracts of kn046, an innovative pd-l1/ctla-4 bispecific antibody, were received by the annual meeting of chinese society of clinical oncology (csc...
06 september 2019

a phase ii clinical trial launched for kn046 in combination with chemotherapy in advanced nsclc alphamab oncology, a leading clinical-stage biopharmaceutical company in china, announced today that a phase ii clinical study has been launched for kn046 in combination with chemotherapy to evaluate ...
26 june 2019

alphamab oncology initiates the us phase i clinical trial for kn026 suzhou, china, june 26, 2019 - alphamb oncology announced that kno26, an anti-her2 bispecific antibody independently developed by the company, has entered phase i clinical trial in the united states a...